Skip to main content

Table 9 Summary of recent published studies of PD-L1 expression in breast cancer using FDA-approved clones

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

ReferenceNo., type of breast tumorsClonesPathologic materialCutoffs for positive/high stainingCorrelation with prognosis
He et al. [16]68, IBC, post NACT28–8TMATC > 1%Worse prognosis
Humphries et al. [17]≥ 109, various typesSP142TMA> 1%, epithelial and lymphoid cellsBetter prognosis
Karnik et al. [18]136, ductal (primary and metastasis)22C3, SP263WSS (biopsies and resections)TC ≥ 1%Not performed
Li et al. [19]191, HER2 positive, no NACT22C3, 28–8TMATC ≥ 1%; IC, cutoff not definedBetter prognosis
Pelekanou et al. [20]163, HER2 negative, locally advanced, or IBC (120, pretreatment; 43, post NACT)22C3WSSEither tumor or stromal cells ≥ 1%Not associated (but better pCR)
Downes et al. [21]30, not specified22C3, SP142, SP263TMA22C3: CPS ≥ 1; SP142: IC ≥ 1%; SP263: cutoff not definedNot performed
Noske et al. [22]1318, various types, all node-positiveSP263TMATC ≥ 1%; IC ≥ 1%Not associated
Van Berckelaer et al. [23]349 (207, pretreatment IBC; 142, non-IBC)SP142WSS (biopsies)TC, IC (categorized based on %)Not associated (but better pCR)
  1. IBC inflammatory carcinoma, NACT neoadjuvant chemotherapy, TC tumor cell, IC immune cell, CPS combined positive score, TMA tissue microarray, WSS whole slide section, pCR pathologic complete response